An early identification of non-responders in oncology is of crucial importance to rapidly switch treatment regimens. Here we report a positron emission tomography, (PET)-guided switch from immunotherapy to targeted therapy in a patient affected by metastatic melanoma. We describe the case of a 78-years-old male patient diagnosed with nodular melanoma, submitted to baseline PET/CT with 18fluorodeoxyglucose (18F-FDG) that showed cutaneous and skeletal metastases (stage IV). The patients started immunotherapy with pembrolizumab. A PET/CT performed 3 months after the start of immunotherapy demonstrated progressive metabolic disease both at skeletal and cutaneous level, confirmed also by the biopsy. As patients resulted positive for BRAF V600k mutation, treatment regimen was rapidly switched to combined anti-BRAF/MEK targeted therapy. The PET/CT performed 3 months later, showed almost complete metabolic response. Ten months after the beginning of targeted therapy, the patient continues to present a durable metabolic response. PET/CT with 18F-FDG may help in monitoring the response to treatment in metastatic melanoma thus defining personalized therapeutic pathways.

PET-guided switch from immunotherapy to targeted therapy in a metastatic melanoma patients. A personalized approach / Proietti, I; Filippi, L; Michelini, S; Porta, N; Bernardini, N; Mambrin, A; Tolino, E; Pacini, L; Rosa, P; Calogero, A; Romeo, G; Di Cristofano, C; Petrozza, V; Bagni, O; Skroza, N; Potenza, C.. - In: LA CLINICA TERAPEUTICA. - ISSN 0009-9074. - 4:171(2020), pp. e283-e287. [10.7417/CT.2020.2228]

PET-guided switch from immunotherapy to targeted therapy in a metastatic melanoma patients. A personalized approach

Proietti I;Michelini S;Bernardini N;Mambrin A;Tolino E;Pacini L;Rosa P;Calogero A;Romeo G;Di Cristofano C;Petrozza V;Skroza N;Potenza C.
2020

Abstract

An early identification of non-responders in oncology is of crucial importance to rapidly switch treatment regimens. Here we report a positron emission tomography, (PET)-guided switch from immunotherapy to targeted therapy in a patient affected by metastatic melanoma. We describe the case of a 78-years-old male patient diagnosed with nodular melanoma, submitted to baseline PET/CT with 18fluorodeoxyglucose (18F-FDG) that showed cutaneous and skeletal metastases (stage IV). The patients started immunotherapy with pembrolizumab. A PET/CT performed 3 months after the start of immunotherapy demonstrated progressive metabolic disease both at skeletal and cutaneous level, confirmed also by the biopsy. As patients resulted positive for BRAF V600k mutation, treatment regimen was rapidly switched to combined anti-BRAF/MEK targeted therapy. The PET/CT performed 3 months later, showed almost complete metabolic response. Ten months after the beginning of targeted therapy, the patient continues to present a durable metabolic response. PET/CT with 18F-FDG may help in monitoring the response to treatment in metastatic melanoma thus defining personalized therapeutic pathways.
2020
BRAF mutation; immunotherapy; melanoma; positron emission tomography; targeted therapy
01 Pubblicazione su rivista::01i Case report
PET-guided switch from immunotherapy to targeted therapy in a metastatic melanoma patients. A personalized approach / Proietti, I; Filippi, L; Michelini, S; Porta, N; Bernardini, N; Mambrin, A; Tolino, E; Pacini, L; Rosa, P; Calogero, A; Romeo, G; Di Cristofano, C; Petrozza, V; Bagni, O; Skroza, N; Potenza, C.. - In: LA CLINICA TERAPEUTICA. - ISSN 0009-9074. - 4:171(2020), pp. e283-e287. [10.7417/CT.2020.2228]
File allegati a questo prodotto
File Dimensione Formato  
Proietti_PET-guided_2020.pdf

accesso aperto

Tipologia: Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza: Tutti i diritti riservati (All rights reserved)
Dimensione 1.19 MB
Formato Adobe PDF
1.19 MB Adobe PDF

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/1427226
Citazioni
  • ???jsp.display-item.citation.pmc??? 0
  • Scopus 0
  • ???jsp.display-item.citation.isi??? 0
social impact